Trialszenagamtidetirzepatidenovo nordiskobesity

Novo Nordisk registers Phase 1 trial switching tirzepatide patients to zenagamtide

The open-label, multiple-arm study will test which zenagamtide dose patients can move to from a maintenance dose of tirzepatide.

By Priya Raman · Science Reporter

Oct 9 08:00 ETSource: ClinicalTrials.gov

The wire

01NCT07868354, sponsored by Novo Nordisk, is an open-label multiple-arm Phase 1 tolerability study in adults with overweight or obesity, with or without type 2 diabetes, starting 8 October 2026.
02Switching protocols between incretin agents are a practical gap for prescribers; the trial is designed to identify a tolerable zenagamtide starting dose after tirzepatide maintenance.
03The study is listed as not yet recruiting, and no enrollment target, dose range or efficacy endpoints are given in the registration.

From the source

A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
NCT07868354 · PHASE1 · NOT YET RECRUITING · Sponsor: Novo Nordisk A/S · Conditions: Overweight, Obesity, Type 2 Diabetes.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07868354